Novavax RSV F Vaccine Clinical Trial Data in Women of Child Bearing Age Published in the Journal of Infectious Disease

GAITHERSBURG, Md., Sept. 10, 2015 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the full data set from its clinical trial of the RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in women of childbearing age (18-35 years) were published in the Journal of Infectious Disease. The Company previously announced top-line results from the trial.

The manuscript describes the randomized, blinded, placebo-controlled Phase 2 clinical trial that evaluated the safety and immunogenicity of two dose levels of the RSV F Vaccine with and without aluminum phosphate adjuvant. The trial enrolled 330 women of childbearing age who received either one or two intramuscular injections of a single-dose (60 or 90 µg) of vaccine or placebo at study days 0 and 28.